APA

Beelen K., Opdam M., Severson T. M., Koornstra R. H. T., Vincent A. D., Hauptmann M., van Schaik R. H. N., Berns E. M. J. J., Vermorken J. B., van Diest P. J. & Linn S. C. (20140127). CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. : Breast cancer research and treatment.

Chicago

Beelen K, Opdam M, Severson T M, Koornstra R H T, Vincent A D, Hauptmann M, van Schaik R H N, Berns E M J J, Vermorken J B, van Diest P J and Linn S C. 20140127. CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. : Breast cancer research and treatment.

Harvard

Beelen K., Opdam M., Severson T. M., Koornstra R. H. T., Vincent A. D., Hauptmann M., van Schaik R. H. N., Berns E. M. J. J., Vermorken J. B., van Diest P. J. and Linn S. C. (20140127). CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. : Breast cancer research and treatment.

MLA

Beelen K, Opdam M, Severson T M, Koornstra R H T, Vincent A D, Hauptmann M, van Schaik R H N, Berns E M J J, Vermorken J B, van Diest P J and Linn S C. CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. : Breast cancer research and treatment. 20140127.